A woman with incurable breast cancer is celebrating after Pharmac announced funding for a new drug that offers her hope for extending her life. Maggie Ngatai had been facing a heart-wrenching choice of raising $175,000 for the medication Enhertu, or accepting her diminished prognosis.
Hope Restored: Enhertu Now Accessible Through Pharmac
Pharmac announced on Friday that it would fund four new medications for people battling various types of breast and lung cancer, along with two respiratory conditions. Crucially, the organisation removed some eligibility criteria that had previously limited patient access to these life-saving medications.
This change spells hope for patients like Ms Ngatai, who had previously been denied access to Enhertu. She had faced the unimaginable possibility of having to forgo potentially life-extending treatment due to cost constraints.
Removing the Burden of Cost
“That was sort of the last hope, really,” Ngatai said. “The fact that it was put on the table and then taken off the table was very difficult,” she explained, recounting the emotional rollercoaster she endured after the initial funding decision was made.
Now, with Pharmac’s announcement, Ms Ngatai feels a sense of relief. “Before, there was that balance of what is time worth? And now, that’s taken that stress away somewhat,” she said, describing the weight lifted from her shoulders.
Powerful Drug Set to Transform Treatment
The Breast Cancer Foundation played a crucial role in advocating for patient access to Enhertu. They presented strong clinical trial evidence during Pharmac’s consultation period, demonstrating the drug’s effectiveness for individuals who had not responded well to Kadcyla.
Ah-Leen Rayner, chief executive of the Breast Cancer Foundation, described the drug as “incredible,” highlighting its dual action: blocking the growth and spread of cancer while also destroying cancer cells through chemotherapy.
Reaching Those Who Need It Most
Pharmac’s director of pharmaceuticals Geraldine MacGibbon said that roughly 120 people in New Zealand will benefit from Enhertu in its first year of funding. This number is expected to increase as more patients become eligible for the innovative treatment.
She noted that one in nine New Zealand women are diagnosed with breast cancer at some point in their lives. Of these, approximately 16 percent are classified as HER2-positive, an aggressive form of the disease that often requires targeted therapies like Enhertu.
The Full List ofFunded Medications:
- Osimertinib (branded as Tagrisso) for people with a type of advanced non-small cell lung cancer
- Trastuzumab deruxtecan (branded as Enhertu) for people with HER2-positive metastatic breast cancer
- Palivizumab (branded as Synagis) to prevent RSV in high-risk babies and young children
- Budesonide, glycopyrronium and formoterol triple inhaler (branded as Breztri Aerosphere) for people with chronic obstructive pulmonary disease (COPD)
This news offers renewed hope for patients battling multiple difficult illnesses. For those affected by cancer or respiratory conditions, accessing these crucial medications can mean the difference between life and death.
**To learn more about the funding decisions and how this affects you or someone you know, visit the Pharmac website: [https://www.pharmac.govt.nz/](https://www.pharmac.govt.nz/).
<